BRIEF-Valeant seeking to modify lender agreements - CEO

Tue Aug 9, 2016 10:02am EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

Aug 9 (Reuters) - Valeant Pharmaceuticals comments from slide presentation and conference call:

* Repaid $1.29 bln debt as of Aug. 9; committed to minimum paydown $1.7 bln in 2016

* Core asset sales to reduce debt by more than $5 billion over 18 months

* Valeant CEO says in company is in compliance with bank debt maintenance covenants through 2016 but cushion not as large as he would like

* Core businesses, geographies that represent more than $2 billion revenue

* Valeant says has engaged banks and advisors in review of strategic alternatives; excludes core assets Further company coverage: (Reporting By Rod Nickel)